Blocking hepatic very low-density lipoprotein secretion through genetic or pharmacologic inhibition of microsomal triglyceride transfer protein (Mttp) causes hepatic steatosis, yet the risks for developing hepatic fibrosis are poorly understood. We report that liver-specific Mttp knockout mice (Mttp-LKO) exhibit both steatosis and fibrosis, which is exacerbated by a high-transfat/fructose diet. When crossed into germline liver fatty acid (FA) binding protein null mice (Mttp-LKO, i.e., double knockout mice) hepatic steatosis was greatly diminished and fibrosis prevented, on both low-fat and high-fat diets. The mechanisms underlying protection include reduced long chain FA uptake, shifts in FA distribution (lipidomic profiling), and metabolic turnover, specifically decreased hepatic 18:2 FA and triglyceride species and a shift in 18:2 FA use for oxidation versus incorporation into newly synthesized triglyceride. Double knockout mice were protected against fastinginduced hepatic steatosis (a model of enhanced exogenous FA delivery) yet developed steatosis upon induction of hepatic de novo lipogenesis with fructose feeding. Mttp-LKO mice, on either the liver FA binding protein null or Apobec-1 null background (i.e., apolipoprotein B100 only) exhibited only subtle increases in endoplasmic reticulum stress, suggesting that an altered unfolded protein response is unlikely to account for the attenuated phenotype in double knockout mice. Acute, antisense-mediated liver FA binding protein knockdown in Mttp-LKO mice also reduced FA uptake, increased oxidation versus incorporation of 18:2 species with complete reversal of hepatic steatosis, increased hepatic injury, and worsened fibrosis. Conclusion: Perturbing exogenous hepatic FA use modulates both hepatic steatosis and fibrosis in the setting of hepatic Mttp deletion, adding new insight into the pathophysiological mechanisms and consequences of defective very low-density lipoprotein secretion. (HEPATOLOGY 2017;65:836-852).
Blocking hepatic very low-density lipoprotein secretion through genetic or pharmacologic inhibition of microsomal triglyceride transfer protein (Mttp) causes hepatic steatosis, yet the risks for developing hepatic fibrosis are poorly understood. We report that liver-specific Mttp knockout mice (Mttp-LKO) exhibit both steatosis and fibrosis, which is exacerbated by a high-transfat/fructose diet. When crossed into germline liver fatty acid (FA) binding protein null mice (Mttp-LKO, i.e., double knockout mice) hepatic steatosis was greatly diminished and fibrosis prevented, on both low-fat and high-fat diets.
The mechanisms underlying protection include reduced long chain FA uptake, shifts in FA distribution (lipidomic profiling), and metabolic turnover, specifically decreased hepatic 18:2 FA and triglyceride species and a shift in 18:2 FA use for oxidation versus incorporation into newly synthesized triglyceride. Double knockout mice were protected against fastinginduced hepatic steatosis (a model of enhanced exogenous FA delivery) yet developed steatosis upon induction of hepatic de novo lipogenesis with fructose feeding. Mttp-LKO mice, on either the liver FA binding protein null or Apobec-1 null background (i.e., apolipoprotein B100 only) exhibited only subtle increases in endoplasmic reticulum stress, suggesting that an altered unfolded protein response is unlikely to account for the attenuated phenotype in double knockout mice. Acute, antisense-mediated liver FA binding protein knockdown in Mttp-LKO mice also reduced FA uptake, increased oxidation versus incorporation of 18:2 species with complete reversal of hepatic steatosis, increased hepatic injury, and worsened fibrosis. Conclusion: Perturbing exogenous hepatic FA use modulates both hepatic steatosis and fibrosis in the setting of hepatic Mttp deletion, adding new insight into the pathophysiological mechanisms and consequences of defective very low-density lipoprotein secretion. (HEPATOLOGY 2017; 65:836-852) .
N onalcoholic fatty liver disease includes a spectrum of disorders that may progress to nonalcoholic steatohepatitis (NASH) with fibrosis and end-stage liver disease.
(1) Excess hepatic triglyceride (TG) accumulation reflects persistent imbalance between exogenous (diet and adipose) free fatty acid (FFA) delivery and uptake, driving TG production, (2) and the removal of intrahepatic TG, which is primarily driven by the export of very low-density lipoprotein (VLDL). (3) Human studies provide evidence for both
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increased and decreased hepatic VLDL secretion in nonalcoholic fatty liver disease/NASH. (4, 5) A subset of patients, however, develop hepatic steatosis and nonalcoholic fatty liver disease driven exclusively by defective VLDL secretion, caused by autosomal mutations in either of two gatekeeper genes involved in VLDL assembly: apolipoprotein B (APOB, the defective gene in familial hypobetalipoproteinemia) and microsomal TG transfer protein (MTTP, the defective gene in abetalipoproteinemia). However, even within this subset of patients, the factors predicting progression of hepatic steatosis to fibrosis are poorly understood. (6) Because of the accompanying hypolipidemia in patients with blocked VLDL secretion, there is considerable interest in exploiting this defect as a therapeutic strategy for patients with severe hypercholesterolemia. (7) However, as indicated above, there remain long-term safety concerns with this strategy. (8) (9) (10) Earlier work in mice demonstrated that either pharmacologic inhibition or genetic deletion of Mttp caused simple hepatic steatosis. (11, 12) Moreover, the hepatic steatosis developing in mice with liver-specific knockout of Mttp (Mttp-LKO) was not associated with insulin resistance or features of the metabolic syndrome. (11, 13) While those earlier reports suggested that blocking VLDL secretion might be well tolerated, other reports have suggested that Mttp inhibition in mice induces endoplasmic reticulum (ER) stress, (14) raising the possibility that Mttp inhibition or deletion may promote or exacerbate liver injury. (12) Our prior work identified liver fatty acid (FA) binding protein (L-Fabp, Fabp1) as a genetic modifier of hepatic steatosis in mice, (15) as evidenced by decreased steatosis in L-Fabp -/-mice following fasting (16) or a high-fat diet (17) (notably in the C57BL6/J background (18) ) and attenuated stellate cell activation and fibrogenesis with diet-induced NASH. (19) These findings reinforce earlier findings in subjects with NASH, where L-Fabp was identified as a biomarker of disease progression in a proteomic screen. (20) We explored the long-term sequelae of Mttp inhibition, showing that Mttp-LKO mice develop fibrosis when fed a low-fat diet, which was exacerbated with diet-induced NASH. We show that the hepatic steatosis and fibrosis in Mttp-LKO mice (on both low-fat and high-fat diets) was attenuated when these mice were crossed into the L-Fabp -/-background, through mechanisms that include altered FA uptake and shifts in long chain FA use. We further show that acute antisense-mediated L-Fabp knockdown in Mttp-LKO mice replicated the metabolic phenotypes with lifelong L-Fabp deletion yet led to hepatic inflammation and exacerbated fibrosis. These findings suggest that strategies to modify FA use offer novel insights into the pathophysiological mechanisms and consequences of defective VLDL secretion.
Materials and Methods
Expanded descriptions for reagents, mouse genotyping, maintenance, dietary regimens, hepatocyte isolation, and metabolic studies are in the Supporting Information.
ANIMALS
Liver-specific Mttp knockout mice (Mttp-LKO) were generated as described (21) and crossed with germline L-Fabp -/-mice (21) (22) to generate Apobec-1 -/-Mttp-DKO mice. All lines were C57BL/6J congenic, and age-matched and sexmatched C57BL/6J mice purchased from Jackson Labs (no. 000664) were used as controls.
TARGETED LIPIDOMICS
Lipids were extracted from 50 lL of liver homogenate with an internal standard mixture. Extracted
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FFAs were derivatized by amino methyl phenyl pyridium in order to obtain high sensitivity in mass spectrometry. Lipids were measured with a Shimadzu 10A high-performance liquid chromatography system and a Shimadzu SIL-20AC HT autosampler coupled to a Thermo Scientific TSQ Quantum Ultra triple quadrupole mass spectrometer operated in selected reaction monitoring mode under electrospray ionization. Data processing was conducted with Xcalibur (Thermo).
Results

DELETION OF L-Fabp IN Mttp-LKO MICE DECREASED STEATOSIS AND LIPID DROPLET SIZE
Liver-specific deletion of Mttp was verified in both L-Fabp-sufficient (Mttp-LKO) and L-Fabp-deficient (Mttp-LKO L-Fabp -/-mice, i.e., DKO mice; Fig 1A) mice. Mttp deletion caused hepatic steatosis by 12 weeks of age in mice fed a low-fat, chow diet (Fig.  1B) , with accumulation of osmium-staining lipid droplets (LDs) (Fig. 1C) . DKO mice exhibited reduced hepatic steatosis, with a shift to smaller LDs (Fig. 1C,D) . We examined whether this shift in LD size correlated with a change in expression of specific LD proteins, but we found only the expression of perilipin 2 to be increased (versus controls), with no difference between Mttp-LKO and DKO genotypes (Fig. 1E ).
LIVER-SPECIFIC Mttp DELETION INDUCES HEPATIC STELLATE CELL ACTIVATION AND FIBROSIS
In agreement with earlier studies showing that blocking VLDL secretion in mice does not cause inflammation or provoke an unfolded protein response, (11, 12) we found no increase in serum transaminases in chow-fed Mttp-LKO mice (Supporting Table S1 ), yet those mice exhibited both increased fibrosis ( Fig. 2A,B ) and increased hydroxyproline content (Fig. 2C ) compared to age-matched, wild-type (WT) controls. By contrast and despite elevated TG content when compared to controls (Fig. 1B) , DKO mice were completely protected against hepatic fibrosis ( Fig. 2A-C) . Fibrogenic mRNA expression was also up-regulated in livers from Mttp-LKO mice, including collagen 1a1, a-smooth muscle actin, osteopontin, connective tissue growth factor, and keratin 19 ( Fig. 2D) , while DKO mice showed no evidence of increased fibrogenesis. These differences in fibrogenesis, however, were not generally reflected in the expression pattern of genes related to transforming growth factor b (TGFb) signaling in the liver with increased mRNA abundance of Tgfb1 and bone morphogenetic protein 2 in both Mttp-LKO genotypes and only small changes in other mRNAs (Fig. 2E ). Lipid peroxidation was also increased in Mttp-LKO mice, and again this was completely attenuated in DKO mice (Fig. 2F ). These data suggest that increased steatosis in Mttp-LKO mice promotes fibrosis and oxidative stress and that deletion of L-Fabp prevents this, at least in part, by reducing hepatic TG accumulation.
We next examined fibrotic injury in Mttp-LKO mice fed a high-transfat/fructose-enriched (TFF) diet, a combination shown to produce a NASH-like phenotype with hepatocyte ballooning and fibrosis. (19) Control mice fed a TFF diet for 16 weeks exhibited the expected increase in hepatic TG content (compare Fig. 3A to Fig. 1B ), an effect magnified in Mttp-LKO mice, while DKO mice exhibited virtually identical hepatic TG content compared to WT (Fig. 3A ). In parallel with these changes, hepatic fibrosis was also increased in Mttp-LKO mice, evidenced by both trichrome and sirius red staining (Fig. 3B,C) . DKO mice exhibited reduced hepatic fibrosis and reduced fibrogenic mRNA expression compared to Mttp-LKO mice ( Fig. 3B-D) . These findings (in female mice) were further replicated in male mice (Supporting Fig. S1 ). As noted above in chow-fed mice, the differences in fibrosis between Mttp-LKO and DKO mice were not reflected by changes in TGFb signaling pathways (Fig. 3E ). In addition, while the hepatic steatosis accompanying liver-specific Mttp deletion has been shown not to promote hepatic insulin resistance, (13) Mttp-LKO mice fed the TFF diet showed a nonsignificant trend to increased homeostasis model assessment of insulin resistance (HOMA-IR) versus WT mice with reduced HOMA-IR in DKO mice (Fig. 3F) . These findings together demonstrate that L-Fabp deletion in the setting of blocked VLDL secretion completely prevents the increased steatosis associated with high-fat diet feeding and prevents the development of hepatic fibrosis.
HEPATIC DELETION OF Mttp PRODUCES ONLY SUBTLE INCREASES IN ER STRESS WITH NO EXACERBATION IN apoB100-ONLY BACKGROUND
Most studies in which mice were either fed Mttp inhibitors or subjected to short-term, liver-specific Mttp deletion showed no evidence of enhanced ER Quantitation of protein expression data (n 5 4/genotype). eIF2a expression is presented as a ratio of phosphorylated to total eIF2a, normalized to C57BL/6J. CHOP and Grp78 expression is normalized to GAPDH and expressed relative to C57BL/6J. *P < 0.05 versus C57BL/6J; # P < 0.05 in DKO versus Mttp-LKO. Abbreviations: Atf4, activating transcription factor 4; Col1a1, collagen type 1a1; Ern1, endoplasmic reticulum to nucleus signaling 1; Gapdh, glyceraldehyde 3-phosphate dehydrogenase; Grp78, 78-kDa glucoseregulated protein; p-, phosphorylated; SMA, smooth muscle actin; t-, total; Xbp1s, X-box binding protein 1s. stress despite increased hepatic steatosis and transaminase elevations. (11, 12, 14, 23) However, those studies were undertaken in mice where the majority of hepatic apoB was the edited mRNA form, apoB48, rather than apoB100. (24) This consideration is relevant as other studies have shown that dysregulation of hepatic apoB100 expression provokes ER stress, which contributes to steatotic injury. (25, 26) In addition, we previously demonstrated that Apobec-1 deletion in intestine-specific Mttp knockout mice exacerbated ER stress particularly with high-fat feeding. (27) Accordingly, we evaluated ER stress in Mttp-LKO mice with a view to understanding the effects of combined deletion of Mttp and Apobec-1 using Apobec-1 -/-Mttp-LKO mice in which there is only apoB100. (24) Those studies revealed comparable increases in hepatic TG in both Mttp-LKO mice (Fig. 4A) and Apobec-1 -/-Mttp-LKO mice. Moreover, we observed no difference in hepatic fibrosis between these mice, assessed by either fibrogenic mRNA expression (collagen 1a1, a-smooth muscle actin mRNA) or sirius redstained fibrotic area (Fig. 4B) . Similar findings were obtained in Apobec-1 -/-Mttp-LKO mice fed the TFF diet, with no evidence of enhanced fibrosis compared to Mttp-LKO mice (Supporting Fig. S2) . A survey of genes related to ER stress revealed no dramatic increases in expression of ER stress genes in any of the three Mttp-LKO genotypes compared to WT (Fig.  4C) , with the exception of a slight (albeit statistically significant) increase in CCAAT/enhancer-binding protein homologous protein (CHOP) mRNA in LFabp Mttp-DKO mice. This subtle increase in mRNA correlated with significantly increased CHOP in all Mttp-LKO genotypes (Fig. 4D,E) . In addition, there was a trend to increased phosphorylated eukaryotic initiation factor 2a (eIF2a, normalized to total eIF2a) in all three Mttp-LKO genotypes compared to WT. These data suggest that activation of the fibrogenic program in Mttp-LKO mice is not driven primarily by changes in hepatic ER stress or by dysregulation of hepatic apoB100 because there were only subtle differences between the Mttp-LKO genotypes.
REDUCED ABUNDANCE OF POLYUNSATURATED FA SPECIES IN DKO MICE
To begin to explore how deletion of L-Fabp attenuates hepatic fibrosis in the setting of reduced hepatic steatosis, we undertook targeted hepatic lipidomic profiling. Total FFA levels were not altered (FFA peak area, Mttp-LKO 9.4 6 0.1, DKO 8.7 6 0.3; n 5 4-5), but there were significant differences in specific FFA species by genotype (Fig. 5A) . Specifically, DKO mice exhibited decreased content of longer chain FFAs, including 18:2, 18:3, and 22:6. These differences were reflected in both an increased de novo lipogenic (DNL) index (a ratio of FA from DNL (16:0) and dietary sources (18:2), respectively) (28) and a decreased stearoyl-coenzyme A desaturase 1 (SCD1) index (16:1/16:0 ratio, a measure of FA saturation (29) ) in DKO mice (Fig. 5A, inset) . Total TG mass was reduced in DKO mice (Mttp-LKO 17.1 6 1.1 peak area, DKO 13.3 6 1.1; n 5 4-5, P 5 0.049) as expected, with a specific reduction in TG species containing polyunsaturated fatty acids (i.e., 16:0, 18:2, 18:2) and fewer changes in species containing saturated or monounsaturated species (i.e., 16:0, 18:1, 18:1) (Fig. 5B) . Again, differences in TG FA species were reflected in altered DNL and SCD1 indices, with changes similar to those observed in FA species (Fig.  5B, inset) . Although the expression of genes involved in FA desaturation (SCD, FADS), elongation (Elovl5, Elovl6), and de novo lipogenesis (Fasn) was dramatically reduced in both Mttp-LKO genotypes compared to WT, there were only minor differences between Mttp-LKO and DKO mice and none consistent with observed differences in FA chain length and saturation (Supporting Fig. S3 ). Together, these data suggest that deletion of L-Fabp affects not only TG accumulation but also the metabolic compartmentalization of specific FA species.
Additional lipidomic profiling in TFF-fed mice revealed comparable hepatic ceramide abundance by genotype (Fig 5C, inset) differences in ceramide species, primarily between WT and Mttp-LKO genotypes (Fig. 5C ). Plasma ceramide levels were decreased in both Mttp-LKO and DKO mice as expected, (30) and we found subtle shifts in lysophosphatidylcholine species (Supporting Fig. S4 ). Because adiponectin has been shown to increase hepatic ceramide synthesis, (31) we measured levels of adiponectin (total and high molecular weight [HMW]) in plasma of TFF-fed mice. While total plasma adiponectin levels were unchanged across the groups, we found reduced levels of HMW adiponectin in both Mttp-LKO genotypes compared to controls (Fig. 5D ). In addition, adiponectin mRNA was reduced in livers of both genotypes of Mttp-LKO mice, with <2-fold changes in mRNA expression of the adiponectin receptors (Supporting Fig. S4C ). Thus, although total hepatic ceramide levels do not vary by genotype, minor changes in HMW adiponectin may alter the metabolism of specific ceramide species in both genotypes of Mttp-LKO mice.
Surprisingly, diacylglyceride (DAG) mass was reduced in Mttp-LKO mice and further reduced in DKO mice (Fig. 5E ). This decrease was further reflected in a reduced abundance of specific DAG species, including 18:1/16:0 and 16:1/18:1 in DKO livers (Fig. 5F ). In addition, the findings revealed a disproportionate increase in the TG/DAG ratio in Mttp-LKO mice (Fig. 5E, right panel) , again suggesting that L-Fabp participates in FA use across many complex lipid species, including mediators of fibrogenic injury.
ALTERED UPTAKE AND METABOLISM OF FAs IN DKO MICE IN VIVO AND IN VITRO
To examine whether the differences in lipidomic profile by genotype could be attributed directly to differences in hepatocyte FA use, we determined FA uptake both in vivo and in primary hepatocytes. Hepatic FA uptake at 10 minutes (normalized for liver size and counts per minute injected) was significantly reduced in DKO mice (Fig. 6A, left panel) , with decreased incorporation into TG (Fig. 6A, right  panel) .
Based upon the findings from lipidomic profiling, we examined the metabolic fates of both [ 3 H]-oleic acid (18:1) and [ 3 H]-linoleic acid (18:2) in primary hepatocytes. Uptake and incorporation of each FA into cellular TG were reduced in DKO mice, with a more striking decrease in DKO cells labeled with linoleic acid (Fig. 6B ). Similar differences were found using a short (15-minute) labeling period (Supporting Fig.  S5 ). In contrast, de novo lipogenesis was unchanged in DKO mice as inferred from [ 14 C]-acetate labeling (Fig. 6B) , suggesting that L-Fabp deletion impairs the use of exogenous long chain FA for TG synthesis but not FA synthesized endogenously. We considered the possibility that decreased expression of hepatic FA transporters could potentially explain reduced FA uptake in DKO hepatocytes. We observed a trend to reduced CD36 mRNA in both Mttp-LKO genotypes and no differences in mRNA abundance of other FA transporter mRNAs that would account for decreased FA uptake (Supporting Fig. S6 ). FA oxidation was also decreased in DKO hepatocytes, suggesting that the reduced FA incorporation into TG does not reflect increased FA oxidation (Fig. 6C) . However, when normalized to net FA uptake, the relative FA oxidation/incorporation ratios for linoleic acid indicated disproportionately greater oxidation of 18:2 FA in DKO hepatocytes, suggesting that FA trafficking, specifically 18:2, is preferentially altered with L-Fabp deletion (Fig. 6D) .
Based upon the shift in LD morphology and number in DKO mice (Fig. 1C,D) , we next examined the $ Significant differences in TG content between 4-hour and 48-hour fast . Middle: Serum b-hydroxybutyrate levels following a 48-hour fast (n 5 4-5/genotype). Right: Hepatic TG in female mice fed a 60% fructose diet for 3 weeks (n 5 7-9 female mice/genotype). Liver TG is significantly increased in fructose-fed mice compared to chow diet for all genotypes. For all panels, *P < 0.05 versus C57BL/6J; # P < 0.05 in DKO versus Mttp-LKO. Abbreviations: DMSO, dimethyl sulfoxide; bHB, b-hydroxybutyrate; ns, not significant. rate of FA-labeled TG turnover in primary hepatocytes, in the presence or absence of triacsin C to block reincorporation of FA. (32) Turnover of TG was similar in [ 3 H]-oleic acid-labeled Mttp-LKO and DKO hepatocytes (Fig. 6E, left panel) , but DKO hepatocytes labeled with [ 3 H]-linoleic acid exhibited reduced cellular TG, both with and without triacsin C (Fig. 6E,  right panel) , suggesting increased turnover of 18:2 containing TG species in DKO hepatocytes. These findings complement the lipidomic data and together suggest that L-Fabp deletion in Mttp-deficient hepatocytes reduces long chain FA uptake and incorporation, preferentially 18:2 FA. Total lipase activity was reduced in DKO mice (Supporting Fig. S7 ), diminishing the likelihood that altered lipolytic processing of LDs might account for the increased turnover observed in the labeling experiments.
We further examined hepatic FA use in the setting of prolonged fasting, which stimulates in vivo turnover and remodeling of hepatocyte LDs. We found the expected increase in hepatic TG in 48 hour-fasted C57BL/6J mice and observed the same trend in Mttp-LKO mice (Fig. 6F) . By contrast, DKO mice showed no increase in hepatic TG after a 48-hour fast, with a corresponding reduction in serum ketones (Fig. 6F,  middle) . There was no difference in serum FFA by genotype (C57BL/6, 0.35 6 0.05 mmol/L; Mttp-LKO, 0.28 6 0.02; DKO, 0.27 6 0.04), indicating that FFA release from adipose was not defective. Expression of several genes related to FAO and ketogenesis was reduced in DKO livers (Supporting Fig.  S8 ), likely a consequence of reduced FA influx. By contrast, we observed similar increases in hepatic steatosis when Mttp-LKO and DKO mice were fed 60% fructose for 3 weeks as inferred by comparable increases in hepatic TG (Fig. 6F, right panel) . Taken together, these data reinforce the conclusion that LFabp deletion does not impair FA use derived from de novo lipogenesis but rather alters FA use from extrahepatic sources.
ACUTE KNOCKDOWN OF L-Fabp REDUCES HEPATIC STEATOSIS YET EXACERBATES INJURY
We next asked if short-term, second-generation antisense oligonucleotide (ASO)-mediated L-Fabp knockdown (L-ASO) in the setting of blocked VLDL secretion could reverse hepatic steatosis and prevent fibrosis in Mttp-LKO mice. Chow fed Mttp-LKO mice treated for 2 weeks with L-ASO showed decreased hepatic TG (Fig. 7A) compared to mice treated with a scrambled ASO (C-ASO), with >80% reduction in L-Fabp mRNA in whole liver as well as in both isolated hepatocytes and stellate cells (Supporting Fig. S9A,B) . Isolated primary hepatocytes from these groups recapitulated the same reduced FA incorporation and increased oxidation/incorporation ratio of both oleate and linoleate (Fig. 7B, right panel) as seen with lifelong genetic deletion of L-Fabp. L-ASOtreated Mttp-LKO mice fed a high-fat TFF diet also exhibited reduced hepatic L-Fabp mRNA (Supporting Fig. S9A ) together with reduced steatosis (Fig. 7C) , decreased lipid peroxidation, as well as decreased abundance of 4-hydroxynonenal-modified proteins by western blotting (Supporting Fig. S10 ). L-ASO-treated TFF-fed mice also exhibited reduced ketogenesis, along with decreased serum glucose and increased circulating levels of FFA (Fig. 7D) .
However, despite a marked reduction in hepatic TG content, L-ASO-treated Mttp-LKO mice exhibited increased injury, with elevated serum alanine aminotransferase and aspartate aminotransferase (Fig. 7E) , and induction of mRNAs related to both fibrogenesis and proliferation (Fig. 7F) . L-ASO-treated mice also showed more extensive fibrosis with increased periportal collagen staining (Fig. 7F) . Expression of CHOP mRNA was increased in L-ASO-treated Mttp-LKO mice (Supporting Fig. S10 ), although other markers of ER stress were unchanged. In addition, we found no difference in p62 expression or in the LC3-II to LC3- I ratio between L-ASO-injected and C-ASO-injected mice (Supporting Fig. S10 ), although the expression of unprocessed LC3b was increased by L-ASO treatment. Together these data imply that alterations in cellular autophagy and ER stress are unlikely to mediate the effects noted.
Discussion
The central goals of this study were, first, to evaluate the long-term sequelae of blocking hepatic VLDL secretion in mice, specifically the development of hepatic fibrosis in Mttp-LKO mice, and, second, to test the hypothesis that genetic alterations in FA uptake and use pathways (by lifelong deletion of LFabp) might mitigate hepatic steatosis in this setting. Our findings demonstrate that Mttp-LKO mice develop hepatic fibrosis even on a low-fat diet, a phenotype exaggerated when those mice were fed a TFF diet. LFabp deletion imposed on the background of Mttp-LKO mice (i.e., DKO mice) attenuated both the steatosis and fibrosis phenotypes. We further show that short-term, ASO-mediated L-Fabp knockdown in Mttp-LKO mice replicated the metabolic phenotypes observed with DKO mice yet caused worse injury and exacerbated hepatic fibrosis. Several elements of these key observations merit additional consideration.
The current studies extend our understanding of the long-term consequences of blocking hepatic VLDL secretion in mice and provide new insights into the mechanisms underlying the progressive NASH that occurs in a significant proportion of patients with defective VLDL assembly (abetalipoproteinemia, familial hypobetalipoproteinemia), who are at risk not only for the predictable development of hepatic steatosis but also for the development of cirrhosis and hepatocellular carcinoma. (6, 33, 34) Among the distinctive features of the progressive liver injury in those patients are the absence of abdominal obesity, systemic inflammation, and insulin resistance, suggesting that the development and progression of NASH in individuals with defective VLDL secretion are driven by different pathways from those in obese, insulin-resistant subjects with metabolic syndrome. (6) The observations in patients with defective VLDL secretion are in line with earlier studies showing normal glucose tolerance and systemic insulin sensitivity in liver-specific Mttp null mice. (13) Other studies showed that liver-specific transgenic acyl-coenzyme A:diacylglycerol acyltransferase 1 (DGAT1) or DGAT2 overexpressing mice exhibited marked steatosis with accumulation of TG as well as lipid intermediates yet failed to manifest hepatic or systemic insulin resistance, suggesting that hepatic steatosis can be uncoupled from insulin resistance. (35) In neither of these models was hepatic inflammation observed, but in neither case was the long-term development of hepatic fibrosis examined. Accordingly, a major implication from the current studies is that the hepatic steatosis resulting from blocked VLDL secretion may lead to fibrosis in the absence of either inflammation or insulin resistance. That being said, our preliminary observations suggest that TFF-fed Mttp-LKO mice may display features of altered insulin sensitivity (as inferred by a trend to increased HOMA index), and the extent of hepatic fibrosis was correspondingly worse than that noted in WT mice fed the same fibrogenic diet (Fig. 3B-D) . While those findings suggest that insulin resistance imposed on the background of blocked VLDL secretion may exacerbate hepatic fibrosis, such a suggestion will require more detailed study of hepatic and systemic insulin resistance.
How can we explain the mediators of liver fibrosis in the setting of blocked VLDL secretion? Our targeted lipidomic profiling revealed shifts in hepatic FA distribution among FFA as well as TG and diacylglycerol species, yet hepatic ceramide content was unchanged and DAG content was actually decreased in Mttp-LKO mice and further decreased in DKO mice. In addition, we found no changes by genotype in the abundance of hepatic lysophosphatidylcholine (Supporting Fig. S4 ), another lipid metabolite strongly implicated in the pathogenesis and progression of NASH. (36) The findings in regard to hepatic ceramide and DAG abundance are at variance with earlier findings that Mttp-LKO mice (using Mx1 Cre induced with pI-pC) exhibit 30% increases in both hepatic ceramide and DAG. (13) However, the Mttp-LKO mice in those studies were generated with a different Cre driver (current studies used albumin Cre), and it is possible that subtle differences in the experimental design (4-hour versus 12-hour fasting) might contribute to the variance in the abundance of lipid intermediates. (13) Other studies showed that small interfering RNA silencing of DGAT2 reduced hepatic steatosis in mice simultaneously treated with a small interfering RNA against Mttp, (37) suggesting that therapeutic strategies to interrupt metabolic pathways involved in TG assembly may yet offer a viable option to mitigate steatosis in the setting of blocked VLDL secretion. However, enthusiasm for that approach must be tempered by findings that DGAT2 ASO treatment in obese mice improved hepatic steatosis but exacerbated liver fibrosis. (38) Another possible consideration as a mediator of the injury with blocked VLDL secretion is hepatic free cholesterol, whose content was increased in Mttp-LKO mice fed a TFF diet (Fig. 3A) but not in DKO mice. Studies have implicated hepatic free cholesterol content as a key determinant of hepatic fibrogenic injury in mice (39, 40) and have found a relationship between NASH progression in human subjects and hepatic free cholesterol content. (41) Precedent exists for a plausible relationship between L-Fabp deletion and hepatic cholesterol use in the setting of blocked VLDL secretion as evidenced by our earlier findings that increased biliary cholesterol secretion and enhanced gallstone formation in L-Fabp knockout mice were completely prevented in DKO mice.
(21) However, we found no difference in hepatic cholesterol content in L-ASO-treated Mttp-LKO mice fed a TFF diet (Fig.  7A) , suggesting that alternative mediators may be involved in that setting. Yet another possibility is that changes in hepatic FFA flux play an important role in the lipotoxic injury phenotype observed. The increased serum FFA levels in Mttp-LKO mice treated with L-ASO (Fig. 7D ) support the suggestion that increased turnover of hepatic LDs in L-ASO-treated mice released FA that was no longer buffered by cytosolic L-Fabp and might contribute to the lipotoxic injury. We speculate that the absence of changes in serum or hepatic FFA in DKO mice reflects the lifelong duration (versus acute knockdown) of L-Fabp deletion in that setting.
There is a caveat to the conclusion that alterations in hepatic FA use by L-Fabp deletion play a dominant role in mitigating both the steatosis and hepatic fibrosis observed following blocked VLDL secretion. In particular, we recognize that DKO mice are germline null for L-Fabp, thus lacking expression in both hepatocytes and small intestinal enterocytes. (16) Accordingly, alterations or compensatory changes in intestinal lipid metabolism may conceivably play a role in the phenotypes observed. Against this possibility is that intestinal FA uptake and lipid absorption were earlier found to be similar in WT and germline L-Fabp knockout mice, suggesting that fat malabsorption is unlikely to account for the phenotypes observed in DKO mice. (17) Furthermore, acute, liver-specific knockdown of L-Fabp by ASO treatment recapitulated the phenotype of the germline knockout (Fig. 7) . These considerations notwithstanding, we observed that ASO treatment led to a rapid (within 2 weeks) decline in L-Fabp expression in both hepatocyte and stellate cells (Supporting Fig. S9B ). Those observations raise the possibility that cell-specific functions for L-Fabp may need to be considered using cell type-specific and tissue-specific L-Fabp deletor lines once those animals are developed.
Finally, the current findings permit us to speculate on the challenges for antisense strategies to interrupt hepatic FA use as a therapeutic target in the setting of blocked VLDL secretion. We observed no evidence of liver injury in L-ASO-treated Mttp-LKO mice fed a chow diet, although the duration of ASO treatment (2 weeks) was much shorter than that employed (8-10 weeks) in mice fed the TFF diet. It is also worth noting that ASO-mediated knockdown of the LD protein perilipin 2 reduced hepatic steatosis in high fat-fed mice and induced hepatic proliferation and fibrogenic gene expression. (42) Those data, taken together with earlier findings demonstrating that ASO-mediated knockdown of perilipin 2 reduced hepatic steatosis and improved insulin sensitivity in both diet-induced obesity as well as genetic models of insulin resistance and fatty liver (Lep ob mice), (43, 44) suggest that further information is needed regarding the mechanisms by which interruption of LD catabolism impacts pathways of hepatic fibrogenesis.
